SC 13G/A: UroGen Pharma Ltd.

AI Summary

SC 13G/A filing by UroGen Pharma Ltd..

Risk Assessment

Risk Level: low

Filing Documents

• urgn13ga2024.htm (SC 13G/A) — 56KB
• 0000935836-24-000143.txt ( ) — 57KB

Ownership

Item 4. Ownership. See Items 5-9 and 11 of the cover page for each Filer.

Ownership of Five Percent or Less of a Class

Item 5. Ownership of Five Percent or Less of a Class If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ X ].

Ownership of More than Five Percent on Behalf of Another Person

Item 6. Ownership of More than Five Percent on Behalf of Another Person. Not applicable. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. Not applicable.

Identification and Classification of Members of the Group

Item 8. Identification and Classification of Members of the Group. Not applicable.

Notice of Dissolution of Group

Item 9. Notice of Dissolution of Group Not applicable.

Material to Be Filed as Exhibits

Item 10. Material to Be Filed as Exhibits Agreement Regarding Joint Filing of Statement on Schedule 13D or 13G.

Certification of the General Partner, Mr. Plexico and Mr. Lynch

Item 11. Certification of the General Partner, Mr. Plexico and Mr. Lynch By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. Certification of the Partnership By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. 7 CUSIP No. M96088105 SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated:February 13, 2024 STONEPINE CAPITAL MANAGEMENT, LLC By: /s/ Timothy P. Lynch Timothy P. Lynch, Managing Member STONEPINE CAPITAL, L.P. By: Stonepine Capital Management, LLC, General Partner By: /s/ Timothy P. Lynch Timothy P. Lynch, Managing Member /s/ Jon M. Plexico Jon M. Plexico /s/ Timothy P. Lynch Timothy P. Lynch 8 CUSIP No. M96088105 EXHIBIT A AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G The undersigned agree to file jointly with the Securities and Exchange Commission (the “SEC”) any and all statements on Schedule 13D or Schedule 13G or Forms 3, 4 or 5(and any amendments or supplements thereto) required under section